Sangamo Therapeutics, Inc. (SGMOQ)
0.171
+0.01
(+4.27%)
USD |
OTCM |
Sep 02, 16:00
Sangamo Therapeutics Cash from Operations (TTM) : -90.34M for March 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -90.34M |
| December 31, 2025 | -97.21M |
| September 30, 2025 | -76.16M |
| June 30, 2025 | -35.90M |
| March 31, 2025 | -44.62M |
| December 31, 2024 | -67.14M |
| September 30, 2024 | -114.33M |
| June 30, 2024 | -173.38M |
| March 31, 2024 | -207.20M |
| December 31, 2023 | -224.84M |
| September 30, 2023 | -231.35M |
| June 30, 2023 | -237.68M |
| March 31, 2023 | -230.95M |
| December 31, 2022 | -223.63M |
| September 30, 2022 | -219.29M |
| June 30, 2022 | -225.09M |
| March 31, 2022 | -223.68M |
| December 31, 2021 | -233.25M |
| September 30, 2021 | -184.83M |
| June 30, 2021 | -92.34M |
| March 31, 2021 | 120.22M |
| December 31, 2020 | 169.88M |
| September 30, 2020 | 153.35M |
| June 30, 2020 | 81.41M |
| March 31, 2020 | -118.17M |
| Date | Value |
|---|---|
| December 31, 2019 | -144.40M |
| September 30, 2019 | -163.14M |
| June 30, 2019 | -151.87M |
| March 31, 2019 | 10.17M |
| December 31, 2018 | 37.15M |
| September 30, 2018 | 59.87M |
| June 30, 2018 | 71.78M |
| March 31, 2018 | 6.123M |
| December 31, 2017 | 11.18M |
| September 30, 2017 | 15.72M |
| June 30, 2017 | 14.36M |
| March 31, 2017 | -58.60M |
| December 31, 2016 | -65.88M |
| September 30, 2016 | -62.68M |
| June 30, 2016 | -59.84M |
| March 31, 2016 | -51.69M |
| December 31, 2015 | -33.72M |
| September 30, 2015 | -27.33M |
| June 30, 2015 | -18.90M |
| March 31, 2015 | -19.45M |
| December 31, 2014 | -5.675M |
| September 30, 2014 | -4.30M |
| June 30, 2014 | -3.046M |
| March 31, 2014 | 0.235M |
| December 31, 2013 | -19.16M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -59.06M |
| Oncolytics Biotech, Inc. | -26.52M |
| Sarepta Therapeutics, Inc. | 93.95M |
| Anixa Biosciences, Inc. | -7.117M |
| Vicapsys Life Sciences, Inc. | -0.1292M |